A multidisciplinary team approach to care is fostered through peer-to-peer discussion and collaboration. The team diagnosis and treatment, includes radiological, pathological findings and immunohistochemical testing, bridges these gaps across the continuum of care in order to enhance the overall quality of patient-centered cancer care.
Medical Oncologists, Radiation Oncologists, General Surgeons, Pathologists, Radiologists, Pharmacists, Nurses, Social Workers, Radiologic Technologists, Patient Care Facilitators and all personnel involved in the care of the cancer patient.
- Implement optimal course of treatment for cancer patients.
- Utilize multiple disciplinary approaches to diagnosis and treatment options, including radiological findings, pathological findings and immunohistochemical testing.
- Determine cancer staging using various imaging modalities.
- Promote a multidisciplinary team approach by bridging gaps across the continuum of care in order to enhance the overall quality of patient-centered cancer care.
MODERATOR: Jessica Buicko Lopez, M.D.
CORE GROUP OF CONTRIBUTORS
Pathologists: Jennifer Olivella, D.O.
Radiologists: Carol Adami, M.D., Darlene Da Costa, M.D., Ariana Alvarez, M.D.
Radiation Oncologists: Alicia Gittleman, M.D., James Parsons, M.D.
Surgeon: Jonathan Waxman, M.D., Lynn Geoffrey, M.D., Jessica Buicko Lopez, M.D.
Medical Oncologists: Felix Rodriguez, M.D., Mindy Bohrer, M.D.
Genetics Professional: Jessica McAfee, ARNP-BC, Dawn Blackshear
Nurse Navigation: Sharon Scruggs, R.N., Michele Goldberg, R.N.
Planning Committee Members: Tony Pineda, CTR, Diana Slone, CTR, Polli Svoboda, RHIT
DISCLOSURES: In accordance with the Standards of Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME), which requires balance, independence, objectivity and scientific rigor in all CME programming, Baptist Health has identified and resolved conflicts of interest of all individuals that control CME content, including faculty, planners and members of the Continuing Medical Education Committee and the Continuing Medical Education Department. Dr. Carol Adami has indicated that she, is on the speaker’s bureau for Myriad Genetics. Dr. John Strasswimmer has indicated that he is on the speaker’s bureau for Genentich Roche and receives grant/research support from Regeron Pharmaceutical. All other contributors and all core group members have indicated that they have no significant financial relationship with commercial interest to disclose. Dr. Adami and Dr. Strasswimmer have indicated that their discussions will not include mention of investigational or off-label usage. In addition, all other moderators do not anticipate comments will include discussion of unapproved off-label use of any products. Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.